Trading Signals: VBIV Stock Price Prediction and Forecast (Thu. May. 4, 2006 - Fri. Jul. 24, 2020)(VBI Vaccines Inc)
| VBIV latest price $5.1350 (-6.04%) ($4.8400 - $5.2600) on Fri. Jul. 24, 2020. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 8.2% (three month average) | | RSI | 74 | | Latest Price | $5.1350(-6.04%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | VBIV declines -3.6% a day on average for past five trading days. | | Weekly Trend | VBIV advances 19.2% a week on average for past two weeks. | | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | | Correlated ETFs | Broad market will support VBIV advance at 0% a week (0% probability)
ACES(-44%) UNG(-25%) SIL(-32%) XBI(-26%) VWO(-55%) | | Factors Impacting VBIV price | VBIV will decline at least -4.1% in a week (0% probabilities).
ARKG(-65%) GDX(-65%) EEM(-46%) ARKK(-43%) IBB(-42%) | | | | | | | | Relative Volatility | | | | | | Market Trend Strength | -4.1% (StdDev 8.2%) | | Hourly BBV | -1.1 () | | Intraday Trend | 0% | | | | | |
|
| 5 Day Moving Average | $5.56(-7.64%) | | 10 Day Moving Average | $5.24(-2%) | | 20 Day Moving Average | $4.37(17.51%) | | To recent high | -16.6% | | To recent low | 2.6% | | Market Cap | $1.184b | | | | | | |
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.VBI's COVID-19 vaccine candidate, VBI-2901, is noteworthy because it could potentially also confer immunity to other coronaviruses which cause diseases like MERS (Middle Eastern Respiratory Syndrome). More importantly, VBI appears to be facing a bottleneck either in its preclinical research or its vaccine manufacturing capabilities. VBI doesn't expect to have the necessary clinical study materials assembled for its COVID-19 vaccine trial before the fourth quarter, meaning that it's roughly a quarter behind Vaxart in the development process. |